Cosmos Health Inc. (COSM)

Current Report Filed: 2026-04-16

Cosmos Health reported record revenue of $65.3M in 2025, up 20% year-over-year, indicating strong growth momentum.
Gross profit surged 83% to $7.9M, and gross margin expanded by 418 basis points, suggesting improved operational efficiency.
Adjusted EPS improved by 82%, and the company's cash position increased 10-fold to $3.5M, strengthening its financial position.

Annual Report Filed: 2026-04-15

Cosmos Health's revenue increased by 16.6% year-over-year in fiscal 2025, driven by growth in its pharmaceutical and nutraceutical segments.
The company's gross margin improved by 2.5 percentage points in fiscal 2025, indicating improved operational efficiency.
Cosmos Health issued $6 million in convertible notes in August 2025, which may provide additional capital to fund growth initiatives.

Insider Trading Filed: 2026-02-13

Grigorios Siokas, the CEO and 10% owner of Cosmos Health Inc., acquired 388,532 shares of the company's common stock at $0.3732 per share through a debt exchange agreement.
This transaction suggests that the CEO is confident in the company's future and is willing to convert his debt into equity, aligning his interests with those of other shareholders.
The reported transaction represents a significant increase in the CEO's direct ownership stake, which could be seen as a positive signal by investors.

Insider Trading Filed: 2026-02-12

Grigorios Siokas, the CEO and 10% owner of Cosmos Health Inc. (COSM), acquired 291,262 shares of the company's common stock at $0.412 per share through a debt exchange agreement, indicating his confidence in the company's prospects.
The debt exchange transaction, where Siokas acquired the shares in exchange for $120,000 in debt owed to him, suggests the company is actively managing its capital structure and liquidity.
Siokas' increased ownership position, now holding 8,473,382 shares directly, aligns his interests with those of other shareholders and demonstrates his commitment to the long-term success of Cosmos Health.

Insider Trading Filed: 2026-01-26

Grigorios Siokas, the CEO and 10% owner of Cosmos Health Inc., has acquired 90,325 additional shares of the company's common stock at a discounted price of $0.4982 per share through a debt exchange agreement.
This transaction indicates that the CEO has confidence in the company's future and is willing to convert debt owed to him into equity, aligning his interests with those of other shareholders.
The acquisition of a significant number of shares by an insider, especially the CEO, can be seen as a positive signal for the company's prospects and may be interpreted as a vote of confidence in the company's future.

Insider Trading Filed: 2026-01-21

Grigorios Siokas, the CEO and 10% owner of Cosmos Health Inc. (COSM), has acquired 353,321 shares of the company's common stock at a price of $0.4953 per share, indicating his confidence in the company's future.
The acquisition of these shares was through a debt exchange agreement, where Siokas exchanged $175,000 in debt owed to him by the company for the shares, suggesting a strategic move to align his interests with shareholders.
The acquisition of these shares increases Siokas's beneficial ownership of Cosmos Health to 8,091,795 shares, or a significant stake of over 10% in the company, further strengthening his position as a key decision-maker.

Insider Trading Filed: 2026-01-15

Grigorios Siokas, the CEO and 10% owner of Cosmos Health Inc. (COSM), acquired 493,495 shares of the company's common stock at $0.4458 per share in a debt exchange agreement.
This transaction suggests Siokas's confidence in the company's future and aligns his interests with those of other shareholders.
The price of $0.4458 per share appears to be the fair market value of the stock, indicating the transaction was conducted at arm's length.

Insider Trading Filed: 2026-01-13

The CEO of Cosmos Health Inc. (COSM), Grigorios Siokas, has acquired an additional 113,185 shares of the company's common stock at a price of $0.5036 per share, increasing his direct ownership to 7,244,979 shares.
This transaction appears to be part of a debt exchange agreement, where Siokas exchanged $57,000 in debt owed to him by the company for the newly acquired shares at the fair market value on the transaction date.
The significant increase in the CEO's direct ownership could signal his confidence in the company's future prospects and his alignment with shareholders' interests.

Insider Trading Filed: 2026-01-09

Grigorios Siokas, the CEO and 10% owner of Cosmos Health Inc. (COSM), acquired 156,190 shares of the company's common stock in a debt exchange transaction at a price of $0.5186 per share.
This transaction increases Siokas's direct beneficial ownership of COSM to 7,131,794 shares, representing a significant stake in the company.
The debt exchange agreement between Siokas and the company suggests the company may have been facing financial challenges, which Siokas is addressing through this transaction.

Insider Trading Filed: 2026-01-08

The CEO, Grigorios Siokas, has acquired a significant number of shares (124,880) at a discounted price of $0.5205 per share, indicating his confidence in the company's future prospects.
The debt exchange agreement between the CEO and the company suggests the company may be in a strong financial position, as it is able to settle outstanding debt through equity issuance.
The CEO's increased ownership, now holding 6,975,604 shares, aligns his interests with those of other shareholders and signals his commitment to the company's long-term success.

Insider Trading Filed: 2026-01-07

Grigorios Siokas, the CEO and 10% owner of Cosmos Health Inc., has acquired an additional 133,953 shares of the company's common stock at $0.5375 per share, increasing his direct ownership to 6,850,724 shares.
The share acquisition was made through a debt exchange agreement, where Siokas exchanged $72,000 in debt owed by the company for the new shares at the fair market value on the transaction date.
This insider buying activity suggests that the CEO is confident in the company's prospects and aligns his interests with those of other shareholders.

Important Information